CN117990903A - Application of anti-PCOLCE antibody in preparation of rheumatoid arthritis supplementary diagnostic product - Google Patents
Application of anti-PCOLCE antibody in preparation of rheumatoid arthritis supplementary diagnostic product Download PDFInfo
- Publication number
- CN117990903A CN117990903A CN202410407445.5A CN202410407445A CN117990903A CN 117990903 A CN117990903 A CN 117990903A CN 202410407445 A CN202410407445 A CN 202410407445A CN 117990903 A CN117990903 A CN 117990903A
- Authority
- CN
- China
- Prior art keywords
- pcolce
- antibody
- rheumatoid arthritis
- patients
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 57
- 239000012502 diagnostic product Substances 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title description 4
- 210000002966 serum Anatomy 0.000 claims abstract description 23
- 238000003745 diagnosis Methods 0.000 claims abstract description 16
- 239000003550 marker Substances 0.000 claims abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 9
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 9
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 8
- 201000008482 osteoarthritis Diseases 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 238000009007 Diagnostic Kit Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000003722 extracellular fluid Anatomy 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000153 supplemental effect Effects 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 abstract description 4
- 230000000552 rheumatic effect Effects 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract description 2
- 208000026278 immune system disease Diseases 0.000 abstract description 2
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 238000002965 ELISA Methods 0.000 description 11
- 101000612134 Homo sapiens Procollagen C-endopeptidase enhancer 1 Proteins 0.000 description 10
- 102100041026 Procollagen C-endopeptidase enhancer 1 Human genes 0.000 description 10
- 229920001213 Polysorbate 20 Polymers 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 102400000112 Katacalcin Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 108010050808 Procollagen Proteins 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 1
- 101001090860 Homo sapiens Myeloblastin Proteins 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100034681 Myeloblastin Human genes 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- GLGAUBPACOBAMV-DOFZRALJSA-N arachidonylcyclopropylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NC1CC1 GLGAUBPACOBAMV-DOFZRALJSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 108010061103 cyclic citrullinated peptide Proteins 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention discloses an application of an anti-PCOLCE antibody in preparing a rheumatoid arthritis supplementing diagnosis product, wherein the anti-PCOLCE antibody is used as a marker, and the product is used for detecting the content of the anti-PCOLCE antibody. According to the invention, compared with the normal healthy people and other common rheumatic immune diseases which are easy to be confused with rheumatoid arthritis, the anti-PCOLCE antibody is obviously increased in serum of a patient suffering from the rheumatoid arthritis, so that the defects that the existing autoantibody commonly used for diagnosis is low in positive rate and 1/3 of patients are negative can be effectively overcome, and the diagnosis value of the rheumatoid arthritis is better supplemented.
Description
Technical Field
The invention relates to the technical field of disease diagnosis, in particular to application of an anti-PCOLCE antibody in preparation of rheumatoid arthritis supplementary diagnosis products.
Background
Rheumatoid arthritis (rheumatoid arthritis, RA) is a chronic, progressive, erosive systemic autoimmune disease that is predominantly represented by symmetric polyarthritis. If the disease can not be diagnosed and treated in time, the disease can be developed into joint stiffness and deformity, thereby seriously affecting the quality of life. The disease progress of RA is rapid, and the disability rate of the treatment is 75% after the treatment, so that the early diagnosis and treatment of RA are important.
Diagnosis of RA relies largely on detection of serum markers, in addition to patient-based clinical manifestations and imaging changes. Currently, the most commonly used diagnostic method in clinic is to detect the anti-citrullinated protein antibody (anti-cyclic citrullinated peptide antibody, ACPA) titres in serum by enzyme-linked immunosorbent assay (enzyme linked immunosorbent assay, ELISA), of which the most commonly used is to detect anti-cyclic citrullinated peptide (cyclic citrullinated peptide, CCP) antibody titres. anti-CCP antibodies are highly specific autoantibodies to RA, but about 2/3 of RA patients antibodies detected positive and currently lack better diagnostic methods for seronegative patients.
Disclosure of Invention
The invention aims to solve the problems in the prior art and provide a novel rheumatoid arthritis biomarker for supplementary diagnosis of rheumatoid arthritis.
The technical scheme of the invention is as follows:
In a first aspect, the invention provides the use of an anti-PCOLCE antibody as a marker for the preparation of a complementary diagnostic product for rheumatoid arthritis for the detection of anti-PCOLCE antibody content.
PCOLCE, collectively referred to as procollagen C endopeptidase enhancer (procollagen C-endopeptidase enhancer), also known as procollagen hydroxyl end protease enhancer (Procollagen COOH-Terminal Proteinase Enhancer, PCEP), is a glycoprotein comprising 449 amino acids. PCOLCE are involved in heparin binding and metallopeptidase inhibitor activity, and enhance the process of decomposing type I procollagen C propeptide into type III procollagen C propeptide by procollagen C protease, participating in the necessary steps of extracellular matrix major fiber component assembly. Previous studies have shown that PCOLCE is an important determinant of bone mechanical properties, geometry and collagen fiber morphology in mammals.
PCOLCE is expressed in various normal organs such as lung, liver, heart, brain and the like, and partial researches report that the PCOLCE can be related to various diseases such as osteosarcoma, myocardial fibrosis, liver fibrosis, keloid and the like. Through a great deal of researches, the invention discovers that compared with normal healthy people and other common rheumatic immune diseases (such as osteoarthritis, systemic lupus erythematosus and Sjogren syndrome) which are easy to confuse with rheumatoid arthritis, the anti-PCOLCE antibody is obviously increased in serum of RA patients, and has better supplementary diagnosis value for RA diagnosis.
Preferably, the biological sample is blood, plasma, serum or interstitial fluid.
Preferably, the product is a detection reagent or a supplementary diagnostic kit.
In a second aspect, the invention provides a product for the supplementary diagnosis of rheumatoid arthritis, the product comprising reagents for detecting anti-PCOLCE antibodies.
Preferably, the product is a detection reagent or a supplementary diagnostic kit.
Preferably, the reagent for detecting the anti-PCOLCE antibody comprises a coating antigen citrullinated polypeptide, and the amino acid sequence of the citrullinated polypeptide is shown as SEQ ID NO. 1.
The invention has the following beneficial effects:
The anti-PCOLCE antibody provided by the invention is used as a marker, has obvious difference with normal healthy people and other common rheumatic immune patients which are easy to be confused with rheumatoid arthritis in RA patients, has sensitivity of 42.86 percent and specificity of 92.44 percent in RA diagnosis, has positive rate of 27.27-31.34 percent in serum anti-CCP antibodies and/or RF negative RA patients, can effectively overcome the defect of low detection accuracy of the conventional antibodies, and has better supplementary diagnosis value for RA diagnosis.
Drawings
FIG. 1 is a graph showing the relative abundance of anti-PCOLCE antibodies detected by ELISA in serum samples of RA patients, healthy people, and other common rheumatic immune patients who are easily confused with rheumatoid arthritis in example 1;
FIG. 2 is a ROC curve of the serum anti-PCOLCE antibody used in example 2 to distinguish RA patients from healthy people and disease controls;
FIG. 3 is a graph showing the relative abundance of anti-PCOLCE antibodies detected by ELISA in serum samples from seronegative RA patients in example 3;
FIG. 4 is a ROC curve for a healthy population and seronegative RA patients differentiated by anti-PCOLCE antibodies in serum in example 3.
Detailed Description
For a better understanding of the present application, reference will now be made in detail to the present embodiments, examples of which are illustrated in the accompanying drawings, wherein the present application is illustrated in the accompanying drawings. All other embodiments, which can be made by those skilled in the art based on the embodiments of the present application without making any inventive effort, shall fall within the scope of the present application. Unless otherwise specified, the instruments and reagents used in the examples were purchased commercially, and the experimental means used were conventional.
EXAMPLE 1 significant increases in serum levels of anti-PCOLCE antibodies in RA patients
The level of anti-PCOLCE antibodies in human serum was specifically probed using a citrullinated BSA polypeptide consisting of 19 amino acids (shanghinode biotechnology limited) using the IEDB website B cell epitope prediction tool to determine PCOLCE epitopes.
Citrullinated polypeptide sequence: K-T-L-P-Cit-G-T-A-K-E-G-Q-G-P-G-P-K-Cit-G (SEQ ID NO. 1), wherein the 5 th and 18 th amino acids in the sequence are citrulline.
In addition to the serum sample tested, the primary reagents used include: the method comprises the steps of binding a coated antigen (the citrullinated polypeptide) with an ELISA plate, detecting an antibody (namely an ELISA secondary antibody, specifically recognizing the coated antigen and binding with horseradish peroxidase), developing a color substrate (namely TMB reagent, catalyzing by horseradish peroxidase, developing color, and presenting a test result according to the color development degree of the substrate), and standardizing serum.
The experimental steps are as follows:
The volume ratio of the serum sample to be tested to the standard serum is 1 by using PBS containing 0.1% BSA and 0.05% Tween-20 as a diluent: dilution of 100.
The coated antigen was diluted to 10. Mu.g/mL with PBS at pH 7.2 and then incubated overnight at 4℃with the addition of 96-well ELISA plates (100. Mu.L/well).
Plates were washed with 300. Mu.L of 0.05% Tween-20 PBST soak 2 min times for a total of 4 times.
Mu.L of PBS containing 2% BSA and 0.05% Tween-20 was added to each well, and the wells were blocked at room temperature for 2 hours.
Plates were washed with 300. Mu.L of 0.05% Tween-20 PBST soak 2 min times for a total of 4 times.
100. Mu.L of diluted serum samples were added to each well and incubated for 2 hours at room temperature.
Plates were washed with 300. Mu.L of 0.05% Tween-20 PBST soak 2 min times for a total of 4 times.
Detection antibody 1:10000 was diluted with PBS containing 0.5% BSA and 0.05% Tween-20 as a diluent, 100. Mu.L was added to each well, and incubated at room temperature for 1 hour.
Plates were washed with 300. Mu.L of 0.05% Tween-20 PBST soak 2 min times for a total of 4 times.
100. Mu.L of TMB reagent was added to each well and incubated at room temperature in the dark for 10-30 min.
The reaction was quenched by the addition of 100. Mu.L of 2M sulfuric acid solution and the absorbance (OD) was read on a microplate reader at 450 nm and 570 nm.
Sample: 119 patients with established Rheumatoid Arthritis (RA) (RA classification: 2010 ACR/EULAR rheumatoid arthritis classification), 41 patients with Osteoarthritis (OA), 45 patients with Systemic Lupus Erythematosus (SLE), 38 patients with Sjogren's Syndrome (SS); healthy Control (HC) 82.
Serum from each sample was collected and detected by enzyme-linked immunosorbent assay (ELISA) using citrullinated polypeptides as coating antigens.
The results of the measurements are shown in the following table and the following graph (Table 1, FIG. 1). The results show that the expression level of anti-PCOLCE antibodies in RA population is significantly higher than in disease control group (osteoarthritis, systemic lupus erythematosus, sjogren syndrome) and healthy control group.
Table 1: expression level of anti-PCOLCE antibodies in RA, OA, SLE, SS and HC populations
Example 2, anti-PCOLCE antibodies have good diagnostic value in RA
The sensitivity and specificity of the anti-PCOLCE antibody were calculated based on the results of example 1.
AU value (Arbitrary units) represents fluorescence intensity, and the calculation formula is: AU= [ OD Peptides -OD Non-specific background ] test serum/[ OD Peptides -OD Non-specific background ] positive serum×100.
The ROC curve was plotted with the true positive rate (sensitivity) as the ordinate and the false positive rate (1-specificity) as the abscissa, and the area of the ROC curve for the anti-PCOLCE antibody was 0.724 (FIG. 2).
Cut-off value: the AU value at which the about log index is maximum, i.e. 19.98, is selected.
The AU value of the serum to be detected is positive when the AU value is higher than the cut-off value.
The AU value at which the about step index is maximum, 19.98, is selected as the cut-off value. Based on this value, the positive rate of anti-PCOLCE antibody in RA patients (42.86%) was significantly higher than in Osteoarthritis (OA) patients (2.44%), systemic lupus erythematosus (systemic lupus erythematosus, SLE) patients (8.88%), sjogren's syndrome, SS) patients (10.53%) and healthy controls (healthy control, HC) (6.10%). The anti PCOLCE antibody has the diagnostic sensitivity and specificity of RA of 42.86 percent and 92.44 percent respectively, and has better diagnostic value.
Example 3 anti-PCOLCE antibodies have better supplementary diagnostic value in seronegative RA
Some RA patients were negative for RA-specific antibodies (RF, anti-CCP antibodies), i.e. seronegative RA. This fraction of patients presents diagnostic difficulties, and we explored the complementary diagnostic value of anti-PCOLCE antibodies in seronegative RA patients.
The serum sample was selected from 137 seronegative RA patients with confirmed diagnosis. ELISA procedure was as in example 1.
The expression levels of anti-PCOLCE antibodies in seronegative RA populations are shown in figure 3 and table 2.
The ROC curve was plotted with the true positive rate (sensitivity) as the ordinate and the false positive rate (1-specificity) as the abscissa, and the area of the ROC curve for the anti-PCOLCE antibody was 0.678 (FIG. 4).
Table 2: expression level of anti-PCOLCE antibodies in established and seronegative RA populations
The anti PCOLCE antibody has good diagnostic value in seronegative RA diagnosis in that the anti CCP antibody is negative RA, RF negative RA and anti CCP antibody is negative, and the positive rate in RF negative RA is 31.34%, 30.00% and 27.27% respectively.
Specific examples are set forth herein to illustrate the invention in detail, and the description of the above examples is only for the purpose of aiding in understanding the core concept of the invention. It should be noted that any obvious modifications, equivalents, or other improvements to those skilled in the art without departing from the inventive concept are intended to be included in the scope of the present invention.
Claims (5)
1. Use of an anti-PCOLCE antibody in the manufacture of a rheumatoid arthritis complement diagnostic product, wherein the anti-PCOLCE antibody is used as a marker, the product comprising reagents for detecting the anti-PCOLCE antibody for detecting the anti-PCOLCE antibody content;
The reagent for detecting the anti-PCOLCE antibody comprises a coating antigen citrullinated polypeptide, and the amino acid sequence of the citrullinated polypeptide is shown as SEQ ID NO. 1.
2. The use according to claim 1, wherein the level of anti-PCOLCE antibodies in the biological sample of rheumatoid arthritis patients is significantly increased relative to normal healthy people, osteoarthritis patients, systemic lupus erythematosus patients and sjogren's syndrome patients.
3. The use according to claim 2, wherein the biological sample is blood, plasma, serum or interstitial fluid.
4. The use according to claim 2, wherein the product is a detection reagent or a supplementary diagnostic kit.
5. A product for the supplemental diagnosis of rheumatoid arthritis, said product comprising reagents for detecting an anti-PCOLCE antibody;
The reagent for detecting the anti-PCOLCE antibody comprises a coating antigen citrullinated polypeptide, and the amino acid sequence of the citrullinated polypeptide is shown as SEQ ID NO. 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410407445.5A CN117990903B (en) | 2024-04-07 | Application of anti-PCOLCE antibody in preparation of rheumatoid arthritis supplementary diagnostic product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410407445.5A CN117990903B (en) | 2024-04-07 | Application of anti-PCOLCE antibody in preparation of rheumatoid arthritis supplementary diagnostic product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117990903A true CN117990903A (en) | 2024-05-07 |
| CN117990903B CN117990903B (en) | 2024-07-16 |
Family
ID=
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1796997A (en) * | 2004-12-22 | 2006-07-05 | 上海富纯中南生物技术有限公司 | Detection kit for diagnosing RA, preparating kit, and method for completing standard of quality detection |
| CN106526196A (en) * | 2016-10-08 | 2017-03-22 | 北京大学人民医院 | Application of SR-A as diagnostic marker and intervention target for rheumatoid arthritis |
| CN110018156A (en) * | 2019-03-27 | 2019-07-16 | 北京大学人民医院(北京大学第二临床医学院) | Application of the anti-CarP antibody as systemic lupus erythematosus diagnosis marker |
| CN111868073A (en) * | 2019-05-31 | 2020-10-30 | 广州市雷德生物科技有限公司 | Specific polypeptide related to rheumatoid arthritis and application thereof |
| CN113774130A (en) * | 2020-06-09 | 2021-12-10 | 碳逻辑生物科技(香港)有限公司 | Biomarkers and methods for selecting a group of chemotherapy responsive patients and uses thereof |
| CN117567626A (en) * | 2024-01-15 | 2024-02-20 | 北京大学人民医院 | Anti-citrullinated scavenger receptor A polypeptide antibody and application thereof in preparation of products for diagnosing rheumatoid arthritis |
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1796997A (en) * | 2004-12-22 | 2006-07-05 | 上海富纯中南生物技术有限公司 | Detection kit for diagnosing RA, preparating kit, and method for completing standard of quality detection |
| CN106526196A (en) * | 2016-10-08 | 2017-03-22 | 北京大学人民医院 | Application of SR-A as diagnostic marker and intervention target for rheumatoid arthritis |
| CN110018156A (en) * | 2019-03-27 | 2019-07-16 | 北京大学人民医院(北京大学第二临床医学院) | Application of the anti-CarP antibody as systemic lupus erythematosus diagnosis marker |
| CN111868073A (en) * | 2019-05-31 | 2020-10-30 | 广州市雷德生物科技有限公司 | Specific polypeptide related to rheumatoid arthritis and application thereof |
| CN113774130A (en) * | 2020-06-09 | 2021-12-10 | 碳逻辑生物科技(香港)有限公司 | Biomarkers and methods for selecting a group of chemotherapy responsive patients and uses thereof |
| CN117567626A (en) * | 2024-01-15 | 2024-02-20 | 北京大学人民医院 | Anti-citrullinated scavenger receptor A polypeptide antibody and application thereof in preparation of products for diagnosing rheumatoid arthritis |
Non-Patent Citations (2)
| Title |
|---|
| PENG HAN等: "Serum Antigenome Profiling Reveals Diagnostic Models for Rheumatoid Arthritis", 《FRONTIERS IN IMMUNOLOGY》, no. 13, 20 April 2022 (2022-04-20), pages 1 - 11 * |
| 张秀英总主编: "《临床风湿病理论与实践》", 30 September 2014, 西安交通大学出版社, pages: 285 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11199549B2 (en) | MEl'hods and means for diagnosing spondylarthritis using autoantibody markers | |
| EP2348049A2 (en) | Novel application of aimp1 polypeptide | |
| US20110065205A1 (en) | Method for determining prognosis of acute central nervous system disorder | |
| CN109738653B (en) | Antigen-protein combination for detection, diagnosis or risk prediction of alzheimer's disease and kit comprising same | |
| US9632098B2 (en) | Moesin fragments and uses thereof | |
| EP2673646B1 (en) | Diagnostic method for urinary tract infection | |
| US10266568B2 (en) | Cyclic citrullinated peptide, rheumatoid arthritis diagnosis composition including the same, rheumatoid arthritis diagnosis method using the peptide or the composition, and method of screening diagnostic marker for rheumatoid arthritis | |
| JP5191544B2 (en) | Dermatomyositis detection method and diagnostic kit | |
| CN110850104A (en) | Protein antigen combination for detecting autoantibodies of Alzheimer's disease and application thereof | |
| CN117990903B (en) | Application of anti-PCOLCE antibody in preparation of rheumatoid arthritis supplementary diagnostic product | |
| CN117990903A (en) | Application of anti-PCOLCE antibody in preparation of rheumatoid arthritis supplementary diagnostic product | |
| JP4685369B2 (en) | Rheumatoid arthritis diagnostic reagent | |
| Hussain et al. | Moesin expression is correlated with its involvement in patients with Behcet’s disease | |
| CN117969827B (en) | Application of anti-caspase 14 antibody in preparing rheumatoid arthritis supplementary diagnosis product | |
| CN113831401B (en) | SLE epitope polypeptide and application thereof in SLE diagnosis | |
| CN107022028B (en) | Specific anti-CitH 3 monoclonal antibody and application of enzyme-linked immunosorbent assay kit thereof in sepsis diagnosis | |
| JP7446882B2 (en) | Test subject screening method and differentiation method | |
| CN113817025B (en) | SLE epitope polypeptides in the identification of SLE and other autoimmune diseases | |
| US20240011984A1 (en) | Proteins for the detection of schistosoma infection | |
| WO2020151631A1 (en) | Rheumatoid arthritis auto-antibody-bound peptide and application thereof | |
| JP2023131930A (en) | Inflammatory bowel disease testing method | |
| CN116334053A (en) | Polypeptide and application thereof in rheumatoid arthritis diagnosis | |
| WO2023275235A1 (en) | Method and means for diagnosis of spondyloarthritis | |
| CN117701577A (en) | Antibody pair, kit and application of anti-CLDN 18.2 fully human monoclonal antibody Fab2 fragment | |
| CN115060907A (en) | ELISA kit for detecting Nogo-B protein expression level |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |